Jyrki Syväri, Pharmacist and Chemist, made his PhD Theses in Pharmaceutical Chemistry and his Diploma in Chemistry in Analytical Chemistry. He joined Boehringer Ingelheim to become a Project Manager in Operations. He was responsible for the worldwide launches of new products, such as Metalyse and Spiriva. Thereafter he was heading a group called “Launch and Special Supplies”. In this function he was responsible for setting up supply chains for Boehringer Ingelheim’s new products. New Supply Chain paradigms and concepts fell also under his responsibility. In this context he became the world-wide program leader for BI’s Product Safety & Security project that centres around serialization. Additionally, Jyrki is leading the global initiative Supply Chain Integrity which takes a broader view on supply chain security, transparency and Risk Management.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key assets of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA.